Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2012

View Archived Issues

New interferon-free therapy for hepatitis C is active in INFORM-SVR trial

AstraZeneca offers overview of first quarter 2012

Genentech presents first small-molecule Ras inhibitors

Apricus Biosciences to meet with Health Canada on Femprox

Exonhit describes novel tubulin polymerization inhibitor

Double-blind trial assesses secukinumab for psoriatic arthritis

Researchers in Taiwan identify new candidate biomarker of kidney injury

Agreement set for development of etanercept and rituximab biosimilars

Generon begins phase II trial of F-627

Mayo Clinic to conduct phase I trials on HER2/Neu antigens

New ALS research partnership launched

Pozen licenses novel migraine therapy to Desitin in Europe

OPKO Health out-licenses prostate cancer biomarker panel

Kineta and collaborators receive biodefense grant

Genta begins phase II trial of tesetaxel in gastric cancer

Roche submits application for anticancer drug in Australia

FDA advisory committee votes on new indication for Arcalyst

Japanese authorities lift approval condition and extend label for Remicade

FDA provides update on Revlimid

GTx gives update on Capesaris IND

Rexahn Pharmaceuticals submits ovarian cancer study protocol to FDA

Ten more European countries recommend approval of Sativex

Boehringer Ingelheim develops new candidate hepatitis therapies

New PI3K inhibitors discovered at Millennium Pharmaceuticals

NoNO divulges novel peptides with therapeutic potential

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...